REBECCA BURKE: Open Payments
NPI 1982031514 · LITTLE ROCK, AR. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,335 in 160 payments from 17 companies in 2025. Trend: 2023 $2,397 · 2024 $3,061 · 2025 $3,335
Food & beverage: $3,327Education: $8
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 18 | $468 |
| Otsuka America Pharmaceutical, Inc. | 20 | $446 |
| Vanda Pharmaceuticals Inc. | 21 | $384 |
| ABBVIE INC. | 19 | $351 |
| Axsome Therapeutics, Inc. | 15 | $299 |
| Neurocrine BioSciences, Inc. | 9 | $208 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $203 |
| Supernus Pharmaceuticals, Inc. | 8 | $202 |
| Teva Pharmaceuticals USA, Inc. | 10 | $199 |
| Janssen Pharmaceuticals, Inc | 9 | $161 |
Products named: REXULTI, CAPLYTA, VRAYLAR, Auvelity, FANAPT, INGREZZA, TRINTELLIX, Qelbree.
Industry payments across AR — which companies pay providers there.
